Clinical Trial Update: Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/2 trial evaluating rapamycin for Activated PI3K-delta syndrome (APDS), a primary immunodeficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Activated Pi3k-delta Syndrome
• Immunodeficiency

Drugs mentioned

• Rapamycin (sirolimus)

Snippet

Sponsor: Children's Hospital of Fudan University | Conditions: Activated PI3K-delta Syndrome, Immunodeficiency Primary | Phase 1, Phase 2 | Status: COMPLETED